Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK
Youre hardly alone
Only 7% of people stopped therapy because of these side effects vs 3% in the placebo group.3 The prevalence of serious adverse events was reported to be 9.8% in the semaglutide group vs 6.4% in placebo group.2 These events include hepatobiliary disorder and gallbladder disorders, most commonly cholelithiasis
In practice, people seek stacks like this for recovery support after training, overuse strain, or periods of reduced mobility, and for comfort related to irritated tendons, ligaments, and joints
Perlmutter leads the movement disorders section of the neurology department and is a professor of neuroscience, of occupational therapy, of physical therapy, and of radiology